Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/29860917/ below:

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

Randomized Controlled Trial

Affiliations

• ¹ From Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); Sunnybrook Research Institute, Toronto (K.I.P.), and McMaster University, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Chicago Stritch School of Medicine, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), and Duke University Medical Center, Durham (J.A.O.) - both in North Carolina; Mayo Clinic, Jacksonville, FL (M.P.G.); National Institutes of Health, National Cancer Institute, Bethesda, MD (T.L., J.A.); Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.), Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Washington University, St. Louis (M.J.E.); National Surgical Adjuvant Breast and Bowel Project Pathology Office (S.P.) and University of Pittsburgh (A.M.B.), Pittsburgh; Emory University, Atlanta (W.C.W.); University of Texas, San Antonio (P.M.R.); Cancer Trials Ireland, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); and University of Hawaii Cancer Center, Honolulu (J.L.B.).

• PMID: 29860917
• PMCID: PMC6172658
• DOI: 10.1056/NEJMoa1804710

Item in Clipboard

Randomized Controlled Trial

Joseph A Sparano et al. N Engl J Med. 2018.

• ¹ From Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); Sunnybrook Research Institute, Toronto (K.I.P.), and McMaster University, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Chicago Stritch School of Medicine, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), and Duke University Medical Center, Durham (J.A.O.) - both in North Carolina; Mayo Clinic, Jacksonville, FL (M.P.G.); National Institutes of Health, National Cancer Institute, Bethesda, MD (T.L., J.A.); Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.), Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Washington University, St. Louis (M.J.E.); National Surgical Adjuvant Breast and Bowel Project Pathology Office (S.P.) and University of Pittsburgh (A.M.B.), Pittsburgh; Emory University, Atlanta (W.C.W.); University of Texas, San Antonio (P.M.R.); Cancer Trials Ireland, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); and University of Hawaii Cancer Center, Honolulu (J.L.B.).

• PMID: 29860917
• PMCID: PMC6172658
• DOI: 10.1056/NEJMoa1804710

Item in Clipboard

Background: The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it is low; however, there is uncertainty about the benefit of chemotherapy for most patients, who have a midrange score.

Methods: We performed a prospective trial involving 10,273 women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer. Of the 9719 eligible patients with follow-up information, 6711 (69%) had a midrange recurrence score of 11 to 25 and were randomly assigned to receive either chemoendocrine therapy or endocrine therapy alone. The trial was designed to show noninferiority of endocrine therapy alone for invasive disease-free survival (defined as freedom from invasive disease recurrence, second primary cancer, or death).

Results: Endocrine therapy was noninferior to chemoendocrine therapy in the analysis of invasive disease-free survival (hazard ratio for invasive disease recurrence, second primary cancer, or death [endocrine vs. chemoendocrine therapy], 1.08; 95% confidence interval, 0.94 to 1.24; P=0.26). At 9 years, the two treatment groups had similar rates of invasive disease-free survival (83.3% in the endocrine-therapy group and 84.3% in the chemoendocrine-therapy group), freedom from disease recurrence at a distant site (94.5% and 95.0%) or at a distant or local-regional site (92.2% and 92.9%), and overall survival (93.9% and 93.8%). The chemotherapy benefit for invasive disease-free survival varied with the combination of recurrence score and age (P=0.004), with some benefit of chemotherapy found in women 50 years of age or younger with a recurrence score of 16 to 25.

Conclusions: Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who had a midrange 21-gene recurrence score, although some benefit of chemotherapy was found in some women 50 years of age or younger. (Funded by the National Cancer Institute and others; TAILORx ClinicalTrials.gov number, NCT00310180 .).

PubMed Disclaimer

All…

All the patients who met the eligibility criteria and…

All the patients who met the eligibility criteria and provided written informed consent were preregistered; a primary tumor specimen was subsequently obtained and sent to the Genomic Health laboratory for the 21-gene assay. On receipt of the assay report and recurrence-score result by the treating physician, the enrolling site then assigned patients to a treatment group. If the recurrence score was 10 or lower, the patient was assigned to receive endocrine therapy alone. If the recurrence score was 26 or higher, the patient was assigned to receive chemoendocrine therapy. If the recurrence score was 11 to 25, the patient underwent randomization and was assigned to receive either endocrine therapy or chemoendocrine therapy. The stratification factors that were used in randomization were tumor size (≤2 cm vs. >2 cm), menopausal status (pre- vs. postmenopausal), planned chemotherapy (taxane-containing vs. not), planned radiation therapy (whole breast and no boost irradiation planned vs. whole breast and boost irradiation planned vs. partial breast irradiation planned vs. no planned radiation therapy for patients who had undergone a mastectomy), and recurrence-score group (11 to 15 vs. 16 to 20 vs. 21 to 25), which was added midway through the trial.

Kaplan–Meier…

Kaplan–Meier estimates of survival rates in the analysis according to the assigned treatment group are shown for the group that received endocrine therapy alone and the group that received chemoendocrine therapy in the intention- to-treat analysis of invasive disease–free survival (defined as freedom from invasive disease recurrence, second primary cancer, or death) and freedom from recurrence of breast cancer at a distant site. The hazard ratios are for the endocrine-therapy group versus the chemoendocrine-therapy group.

• Avoiding overuse of adjuvant therapies.

  Romero D. Romero D. Nat Rev Clin Oncol. 2018 Aug;15(8):469. doi: 10.1038/s41571-018-0054-7. Nat Rev Clin Oncol. 2018. PMID: 29921846 No abstract available.

• TAILORing Adjuvant Systemic Therapy for Breast Cancer.

  Stearns V. Stearns V. N Engl J Med. 2018 Jul 12;379(2):191-192. doi: 10.1056/NEJMe1806329. N Engl J Med. 2018. PMID: 29996081 No abstract available.

• Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.

  Cheng Y, Wu Y, Wu L. Cheng Y, et al. N Engl J Med. 2018 Oct 25;379(17):1680-1. doi: 10.1056/NEJMc1810515. N Engl J Med. 2018. PMID: 30358961 No abstract available.

• Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.

  McCaw ZR, Wei LJ, Kim DH. McCaw ZR, et al. N Engl J Med. 2018 Oct 25;379(17):1681. doi: 10.1056/NEJMc1810515. N Engl J Med. 2018. PMID: 30358968 No abstract available.

• Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer.

  Newman LA. Newman LA. N Engl J Med. 2018 Oct 25;379(17):1681-2. doi: 10.1056/NEJMc1810515. N Engl J Med. 2018. PMID: 30358969 No abstract available.

• The Precision of Evidence Needed to Practice "Precision Medicine".

  Hunter DJ, Longo DL. Hunter DJ, et al. N Engl J Med. 2019 Jun 20;380(25):2472-2474. doi: 10.1056/NEJMe1906088. Epub 2019 Jun 3. N Engl J Med. 2019. PMID: 31157961 No abstract available.

• Adjuvant chemotherapy in early breast cancer: Are we over-treating patients?

  Mittal A, Batra A. Mittal A, et al. Natl Med J India. 2019 Jul-Aug;32(4):230-231. doi: 10.4103/0970-258X.291305. Natl Med J India. 2019. PMID: 32769244 No abstract available.

• 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

  Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. Kalinsky K, et al. N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873. Epub 2021 Dec 1. N Engl J Med. 2021. PMID: 34914339 Free PMC article. Clinical Trial.

• Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

  Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Sparano JA, et al. N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27. N Engl J Med. 2015. PMID: 26412349 Free PMC article. Clinical Trial.

• Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

  Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Sparano JA, et al. N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3. N Engl J Med. 2019. PMID: 31157962 Free PMC article. Clinical Trial.

• Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

  Albain KS, Paik S, van't Veer L. Albain KS, et al. Breast. 2009 Oct;18 Suppl 3:S141-5. doi: 10.1016/S0960-9776(09)70290-5. Breast. 2009. PMID: 19914534 Review.

• Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.

  Giorgi Rossi P, Lebeau A, Canelo-Aybar C, Saz-Parkinson Z, Quinn C, Langendam M, Mcgarrigle H, Warman S, Rigau D, Alonso-Coello P, Broeders M, Graewingholt A, Posso M, Duffy S, Schünemann HJ; ECIBC Contributor Group. Giorgi Rossi P, et al. Br J Cancer. 2021 Apr;124(9):1503-1512. doi: 10.1038/s41416-020-01247-z. Epub 2021 Feb 18. Br J Cancer. 2021. PMID: 33597715 Free PMC article. Review.

• The Impact of Neoadjuvant versus Adjuvant Chemotherapy on Survival Outcomes in Locally Advanced Breast Cancer.

  Ghasemi F, Brackstone M. Ghasemi F, et al. Curr Oncol. 2024 Oct 8;31(10):6007-6016. doi: 10.3390/curroncol31100448. Curr Oncol. 2024. PMID: 39451752 Free PMC article.

• Prognostic Comparison between Oncotype DX^® and a 23-Gene Classifier, RecurIndex^®, on the Taiwan Breast Cancer Population.

  Chang CH, Yang PS, Hsieh CM, Chen TH, Cheng SH, Yang CE, Huang CS. Chang CH, et al. Diagnostics (Basel). 2022 Nov 17;12(11):2850. doi: 10.3390/diagnostics12112850. Diagnostics (Basel). 2022. PMID: 36428912 Free PMC article.

• Five decades of progress in surgical oncology: Breast.

  Downs-Canner S, Cody HS 3rd. Downs-Canner S, et al. J Surg Oncol. 2022 Oct;126(5):852-859. doi: 10.1002/jso.27035. J Surg Oncol. 2022. PMID: 36087082 Free PMC article.

• Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies.

  Turpin A, Neuzillet C, Colle E, Dusetti N, Nicolle R, Cros J, de Mestier L, Bachet JB, Hammel P. Turpin A, et al. Ther Adv Med Oncol. 2022 Sep 6;14:17588359221118019. doi: 10.1177/17588359221118019. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36090800 Free PMC article. Review.

• Staging of the Axilla in Breast Cancer and the Evolving Role of Axillary Ultrasound.

  Chen MY, Gillanders WE. Chen MY, et al. Breast Cancer (Dove Med Press). 2021 May 17;13:311-323. doi: 10.2147/BCTT.S273039. eCollection 2021. Breast Cancer (Dove Med Press). 2021. PMID: 34040436 Free PMC article. Review.

1. 1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893–907. - PubMed
2. 1. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014; 106(5):dju055. - PMC - PubMed
3. 1. Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: an intergroup study. N Engl J Med 1989;320: 485–90. - PubMed
4. 1. Mansour EG, Gray R, Shatila AH, et al. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis — an intergroup study. J Clin Oncol 1998; 16: 3486–92. - PubMed
5. 1. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997;89: 1673–82. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3